The United States has abruptly suspended funding for the President’s Emergency Plan for AIDS Relief (PEPFAR) in South Africa, a move that public health experts warn could unravel decades of progress against HIV. The decision, announced without a detailed explanation, leaves 5.5 million South Africans on antiretroviral therapy in precarious limbo. As a climate and science correspondent, I see this not merely as a political rupture but as a stress test for the resilience of global health infrastructure.
South Africa shoulders the world’s largest HIV burden: 7.8 million people living with the virus, roughly 20% of the global total. PEPFAR has provided approximately 18% of the country’s HIV funding, but its role is far more strategic. It underpins supply chains for generic antiretroviral drugs, supports laboratory networks for viral load testing, and funds 200,000 community health workers who trace patients lost to follow-up. The suspension severs a critical node in a system already strained by recurrent budget cuts and the lingering effects of the COVID-19 pandemic.
The timing is catastrophic. South Africa is currently facing a severe antiretroviral shortage, with the national health department reporting only a 90-day stock of paediatric formulations. The loss of PEPFAR funding will accelerate the depletion of reserves, forcing clinics to ration medications. When patients interrupt therapy, viral loads rebound, increasing transmission risk and fostering drug-resistant strains. Mathematical models from the University of Cape Town project an additional 50,000 AIDS-related deaths over the next five years if the suspension persists.
But the damage extends beyond mortality. Community health workers, many of whom are women from impoverished townships, form the backbone of South Africa’s HIV response. Their stipends are paid through PEPFAR grants. Without them, routine monitoring of patients’ CD4 counts and side effects collapses. The suspension effectively dismantles a human infrastructure that took two decades to build.
This is not a tragedy in isolation. It parallels other funding gaps we observe in climate adaptation: fragile systems propped up by external aid that is withdrawn without transition plans. The energy transition faces similar risks when carbon finance is abruptly cut off. In both cases, the sudden withdrawal of resources does not reset the problem but deepens it, creating feedback loops of instability.
The United States has been the largest bilateral donor for HIV globally, investing over $85 billion in PEPFAR since 2003. The programme saved an estimated 25 million lives. To suspend its funding in the most affected country without a phased exit or alternative financing is akin to shutting down a power grid without building local generation capacity. The ensuing blackout will be measured in lives lost.
South Africa’s health department has announced plans to redirect domestic resources, but the fiscal reality is stark. The national budget allocates only 0.3% of GDP to HIV, far below the 1.5% recommended by UNAIDS. Donor funding remains indispensable. The government cannot simply conjure the R12 billion annual contribution PEPFAR provided.
For the 5.5 million people whose livelihoods of pill-taking depend on an unbroken chain of procurement and logistics, the suspension is an abstract policy shift with visceral consequences. They will feel it when the clinic runs out of tenofovir, when the viral load result takes six weeks instead of two, when the community health worker no longer knocks. This is the granular reality of global health failure.
The suspension also sends a chilling signal to other nations reliant on PEPFAR: 54 countries in sub-Saharan Africa. If funding can be halted in South Africa, no programme is safe. The resulting uncertainty could deter patients from starting therapy, undermining the UNAIDS 95-95-95 targets for epidemic control.
As a scientist, I urge a swift diplomatic resolution. But history suggests that once such funding is severed, the political will to restore it rarely re-emerges with the same urgency. South Africa now faces a choice: accelerate its domestic pharmaceutical production capacity and health financing reforms, or watch a generation of progress reverse. The clock is ticking, and the viral load is rising.